Page 300 - Read Online

potential new therapeutic targets. Oncogene 2018;37:4581-98.
67. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47.
68. Nagasawa J, Govek S, Kahraman M, Lai A, Bonnefous C, et al. Identification of an orally bioavailable chromene-based selective
estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer. J Med Chem
2018;61:7917-28.
69. Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, et al. A first-in-human study of the new oral selective estrogen receptor
degrader AZD9496 for ER(+)/HER2(-) advanced breast cancer. Clin Cancer Res 2018;24:3510-8.
70. Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, et al. Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in
models of endocrine therapy-resistant breast cancer. Clin Cancer Res 2015;21:5121-30.
71. Turner NC, Ro J, Verma S, Huang Bartlett C, Cristofanilli M, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N
Engl J Med 2015;373:209-19.
72. Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, et al. Genomic profiling of ER(+) breast cancers after short-term
estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med 2017;9.
73. Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of
oestrogen receptor-positive breast cancers. Nat Commun 2014;5:4577.
74. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine
therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
75. Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, et al. Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast
cancer. Cell Rep 2018;24:1434-44e7.
76. Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, et al. Randomized phase II trial of fulvestrant alone or in combination
with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York cancer consortium
trial. NPJ Breast Cancer 2016;2:16037.
77. Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine
therapy-resistant breast cancer. Ann Oncol 2018;29:872-80.
78. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes
in prostate cancer. Science 2005;310:644-8.
79. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, et al. Induced chromosomal proximity and gene fusions in prostate cancer.
Science 2009;326:1230.
80. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate
cancer gene rearrangements. Nat Genet 2010;42:668-75.
81. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated
transcription. Science 2006;312:1798-802.
82. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet
2006;38:1289-97.